PT - JOURNAL ARTICLE AU - Matthew K Moore AU - Gregory T Jones AU - Sally McCormick AU - Michael JA Williams AU - Sean Coffey TI - Association between lipoprotein(a), <em>LPA</em> genetic risk score, aortic valve disease, and subsequent major adverse cardiovascular events AID - 10.1101/2023.09.20.23295872 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.20.23295872 4099 - http://medrxiv.org/content/early/2023/09/23/2023.09.20.23295872.short 4100 - http://medrxiv.org/content/early/2023/09/23/2023.09.20.23295872.full AB - Background Cohort studies have demonstrated associations between calcific aortic valve disease (CAVD) and Lp(a). As Lp(a) is almost entirely genetically determined, with the increasing clinical availability of genetic information, we aimed to determine if Lp(a), when predicted from genetic data, is associated with CAVD and major adverse cardiovascular events (MACE).Methods Patients undergoing coronary angiography were invited to participate in the study. Of 752 analysable participants, 446 had Lp(a) measured, and 703 had a calculable LPA genetic risk score (GRS). CAVD was categorized as absent/present and by severity. The primary outcomes were presence of CAVD at baseline, and MACE over seven years follow-up.Results The GRS explained 45% of the variation in Lp(a). After adjustment for cardiac risk factors and coronary artery disease, the odds of CAVD increased with Lp(a) (OR 1.039 per 10 unit increase, 95% C.I. 1.022 – 1.057, p&lt;0.001) and GRS (OR 1.054 per 10-unit increase, 95% C.I. 1.024 – 1.086; p &lt;0.001). Lp(a) and the GRS as continuous variables were not associated with subsequent MACE. Dichotomised GRS (&gt;54) was associated with MACE, but this relationship became non-significant when coronary artery disease classification was added into the model (OR 1.333, 95% C.I. 0.927 – 1.912; p = 0.12).Conclusion An LPA GRS can explain 45% of the variation in Lp(a) levels, and both Lp(a) and the GRS are associated with CAVD. An elevated GRS is associated with future cardiac events in a secondary risk setting, but, if coronary artery disease status is known, it does not provide additional prognostic information.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grants from the Health Research Council of New Zealand (14/155, 17/402, 20/144) and Genomics Aotearoa (a New Zealand Ministry of Business, Innovation and Employment funded research platform). MKM was supported by the New Zealand Heart Foundation and the E &amp; W White Parsons Charitable Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the Upper South A Regional Ethics Committee on 26 January 2012 (Ref: URA/11/11/072).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDue to the New Zealand National Ethical Standards, external data sharing is not permitted.